View Item 

Show simple item record

Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation
dc.contributor.authorKoraishy, Farrukh M.
dc.contributor.authorYamout, Hala
dc.contributor.authorNaik, Abhijit S.
dc.contributor.authorZhang, Zidong
dc.contributor.authorSchnitzler, Mark A.
dc.contributor.authorOuseph, Rosemary
dc.contributor.authorLam, Ngan N.
dc.contributor.authorDharnidharka, Vikas R.
dc.contributor.authorAxelrod, David
dc.contributor.authorHess, Gregory P.
dc.contributor.authorSegev, Dorry L.
dc.contributor.authorKasiske, Bertram L.
dc.contributor.authorLentine, Krista L.
dc.date.accessioned2020-04-02T18:39:29Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-04-02T18:39:29Z
dc.date.issued2020-03
dc.identifier.citationKoraishy, Farrukh M.; Yamout, Hala; Naik, Abhijit S.; Zhang, Zidong; Schnitzler, Mark A.; Ouseph, Rosemary; Lam, Ngan N.; Dharnidharka, Vikas R.; Axelrod, David; Hess, Gregory P.; Segev, Dorry L.; Kasiske, Bertram L.; Lentine, Krista L. (2020). "Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation." Clinical Transplantation 34(3): n/a-n/a.
dc.identifier.issn0902-0063
dc.identifier.issn1399-0012
dc.identifier.urihttps://hdl.handle.net/2027.42/154651
dc.description.abstractHypertension guidelines recommend calcium channel blockers (CCBs), thiazide diuretics, and angiotensin‐converting‐enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) as first‐line agents to treat hypertension. Hypertension is common among kidney transplant (KTx) recipients, but data are limited regarding patterns of antihypertensive medication (AHM) use in this population. We examined a novel database that links national registry data for adult KTx recipients (age > 18 years) with AHM fill records from a pharmaceutical claims warehouse (2007‐2016) to describe use and correlates of AHM use during months 7‐12 post‐transplant. For patients filling AHMs, individual agents used included: dihydropyridine (DHP) CCBs, 55.6%; beta‐blockers (BBs), 52.8%; diuretics, 30.0%; ACEi/ARBs, 21.1%; non‐DHP CCBs, 3.0%; and others, 20.1%. Both BB and ACEi/ARB use were significantly lower in the time period following the 2014 Eighth Joint National Committee (JNC‐8) guidelines (2014‐2016), compared with an earlier period (2007‐2013). The median odds ratios generated from case‐factor adjusted models supported variation in use of ACEi/ARBs (1.51) and BBs (1.55) across transplant centers. Contrary to hypertension guidelines for the general population, KTx recipients are prescribed relatively more BBs and fewer ACEi/ARBs. The clinical impact of this AHM prescribing pattern warrants further study.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherkidney transplant
dc.subject.otherpharmacoepidemiology
dc.subject.otherpractice patterns
dc.subject.otherantihypertensive medications
dc.titleImpacts of center and clinical factors in antihypertensive medication use after kidney transplantation
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154651/1/ctr13803.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154651/2/ctr13803_am.pdf
dc.identifier.doi10.1111/ctr.13803
dc.identifier.sourceClinical Transplantation
dc.identifier.citedreferenceJarari N, Rao N, Peela JR, et al. A review on prescribing patterns of antihypertensive drugs. Clinical hypertension. 2015; 22: 7.
dc.identifier.citedreferenceSaran R, Li Y, Robinson B, et al. Renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016; 67; Svii, S1‐305.
dc.identifier.citedreferenceWeir MR, Burgess ED, Cooper JE, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015; 26: 1248 ‐ 1260.
dc.identifier.citedreferenceMange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA. 2000; 283: 633 ‐ 638.
dc.identifier.citedreferenceOpelz G, Dohler B, Collaborative TS. Improved long‐term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005; 5: 2725 ‐ 2731.
dc.identifier.citedreferenceCross NB, Webster AC, Masson P, O’Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients. Cochrane Database System Rev. 2009; 3: CD003598.
dc.identifier.citedreferenceJames PA, Oparil S, Carter BL, et al. 2014 evidence‐based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507 ‐ 520.
dc.identifier.citedreferenceDunn BL, Teusink AC, Taber DJ, Hemstreet BA, Uber LA, Weimert NA. Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother. 2010; 44: 1259 ‐ 1270.
dc.identifier.citedreferenceLentine KL, Anyaegbu E, Gleisner A, et al. Understanding medical care of transplant recipients through integrated registry and pharmacy claims data. Am J Nephrol. 2013; 38: 420 ‐ 429.
dc.identifier.citedreferenceAxelrod DA, Naik AS, Schnitzler MA, et al. National variation in use of immunosuppression for kidney transplantation: a call for evidence‐based regimen selection. Am J Transplant. 2016; 16: 2453 ‐ 2462.
dc.identifier.citedreferenceDharnidharka VR, Naik AS, Axelrod DA, et al. Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. Transpl Int. 2018; 31: 198 ‐ 211.
dc.identifier.citedreferenceNazzal M, Lentine KL, Naik AS, et al. Center‐driven and clinically driven variation in US liver transplant maintenance immunosuppression therapy: a national practice patterns analysis. Transplant Direct. 2018; 4: e364.
dc.identifier.citedreferenceKing EA, Kucirka LM, McAdams‐DeMarco MA, et al. Early hospital readmission after simultaneous pancreas‐kidney transplantation: patient and center‐level factors. Am J Transplant. 2016; 16: 541 ‐ 549.
dc.identifier.citedreferenceOrandi BJ, James NT, Hall EC, et al. Center‐level variation in the development of delayed graft function after deceased donor kidney transplantation. Transplantation. 2015; 99: 997 ‐ 1002.
dc.identifier.citedreferenceHenderson ML, Thomas AG, Shaffer A, et al. The national landscape of living kidney donor follow‐up in the United States. Am J Transplant. 2017; 17 ( 12 ): 3131 ‐ 3140.
dc.identifier.citedreferenceLentine KL, Naik AS, Schnitzler MA, et al. Variation in use of procurement biopsies and its implications for discard of deceased donor kidneys recovered for transplant. Am J Transplant. 2019; 19: 2241 ‐ 2251.
dc.identifier.citedreferenceMerlo J, Chaix B, Ohlsson H, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health. 2006; 60: 290 ‐ 297.
dc.identifier.citedreferenceChatzikyrkou C, Menne J, Gwinner W, et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens. 2011; 29: 2283 ‐ 2294.
dc.identifier.citedreferenceHiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant. 2007; 7: 2350 ‐ 2360.
dc.identifier.citedreferenceKnoll GA, Fergusson D, Chasse M, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double‐blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4: 318 ‐ 326.
dc.identifier.citedreferenceIbrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol. 2013; 24: 320 ‐ 327.
dc.identifier.citedreferenceCockfield SM, Wilson S, Campbell PM, et al. Comparison of the effects of standard vs low‐dose prolonged‐release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts. Am J Transplant. 2019; 19: 1730 ‐ 1744.
dc.identifier.citedreferenceWright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288: 2421 ‐ 2431.
dc.identifier.citedreferenceWiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta‐blockers for hypertension. Cochrane Database System Rev. 2012; 11: CD002003.
dc.identifier.citedreferenceWiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta‐blockers for hypertension. Cochrane Database System Rev. 2017; 1: CD002003.
dc.identifier.citedreferenceMidtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation. 2001; 72: 1787 ‐ 1792.
dc.identifier.citedreferenceHalimi JM, Persu A, Sarafidis PA, et al. Optimizing hypertension management in renal transplantation: a call to action. Nephrol Dial Transplant. 2017; 32: 1959 ‐ 1962.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ctr13803.pdf
Size:
978.1KB
Format:
PDF
View/Open
Name:
ctr13803_am.pdf
Size:
251.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.